This chapter provides a brief introduction to nucleic acid-based vaccines and recent research in developing self-amplifying mRNA vaccines. These vaccines promise the flexibility of plasmid DNA vaccines with enhanced immunogenicity and safety. The key to realizing the full potential of these vaccines is...
Self-amplifying RNA vaccines和Self-replicating RNA vaccines是同义词。 Self-replicating (or self-amplifying) RNA vaccines consist of an RNA coding for the viral antigen and the virus’ replication machinery, allowing for abundant production of viral antigen. mRNA vaccines — a new era in vaccinology...
and HIV-1. Self-amplifying RNAs have shown enhanced antigen expression at lower doses compared to conventional mRNA, suggesting this technology may improve immunization. This review will explore how self-amplifying RNAs are emerging as important vaccine candidates for infectious diseases, the advantages...
Self-amplifying mRNA (samRNA) is rapidly emerging as a well-tolerated, scalable and widely-applicable platform technology which can be used to develop multiple vaccines simply by changing the sequence of the antigen (the target ...
Combination of waning immunity and lower effectiveness against new SARS-CoV-2 variants of approved COVID-19 vaccines necessitates new vaccines. We evaluated two doses, 28 days apart, of ARCT-154, a self-amplifying mRNA COVID-19 vaccine, compared with saline placebo in an integrated phase 1/...
[3] Bloom et al., (2020). Self-amplifying RNA vaccines for infectious diseases. Gene Therapy, https://doi.org/10.1038/s41434-020-00204-y 注:本文旨在介绍医药健康研究进展,不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。
development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA v...
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results Abstract Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low immune reactivity. T cell-inducing vaccines ...
RNA-based vaccines are an attractive candidate for this role: they are safe, are produced cell free, and can be rapidly generated in response to pathogen emergence. Two RNA vaccine platforms are available: synthetic mRNA molecules encoding only the antigen of interest and self-amplifying RNA (sa...
The doses ranged from 0.1 micrograms to 10 micrograms of saRNA , with 87 percent of people generating antibodies to SARS-CoV-2, the virus that causes COVID-19. For comparison, the Moderna and Pfizer mRNA vaccines have dosages of 100 and 30 micrograms, respectively. ...